BioTelemetry Inc. (BEAT) Reaches New 52-Week High at $19.25
Shares of BioTelemetry Inc. (NASDAQ:BEAT) hit a new 52-week high during mid-day trading on Monday . The company traded as high as $19.25 and last traded at $19.13, with a volume of 369,919 shares traded. The stock had previously closed at $19.02.
Separately, Zacks Investment Research raised BioTelemetry from a “hold” rating to a “strong-buy” rating and set a $18.00 price target on the stock in a research note on Thursday, April 28th.
The stock has a market cap of $535.29 million and a PE ratio of 48.58. The stock has a 50 day moving average price of $16.96 and a 200 day moving average price of $13.86.
Other large investors have bought and sold shares of the company. Gabelli Funds LLC acquired a new stake in BioTelemetry during the fourth quarter worth approximately $1,190,000. Russell Frank Co increased its stake in BioTelemetry by 58.9% in the fourth quarter. Russell Frank Co now owns 249,457 shares of the company’s stock worth $2,933,000 after buying an additional 92,455 shares in the last quarter. 1492 Capital Management LLC increased its stake in BioTelemetry by 11.4% in the fourth quarter. 1492 Capital Management LLC now owns 321,761 shares of the company’s stock worth $3,758,000 after buying an additional 32,932 shares in the last quarter. Royce & Associates LLC increased its stake in BioTelemetry by 102.2% in the fourth quarter. Royce & Associates LLC now owns 606,700 shares of the company’s stock worth $7,086,000 after buying an additional 306,700 shares in the last quarter. Finally, Wells Fargo & Company MN increased its stake in BioTelemetry by 13.6% in the fourth quarter. Wells Fargo & Company MN now owns 994,163 shares of the company’s stock worth $11,612,000 after buying an additional 119,328 shares in the last quarter.
BioTelemetry, Inc (BioTelemetry), formerly CardioNet, Inc, provides cardiac monitoring services, cardiac monitoring device manufacturing, and centralized cardiac core laboratory services. The Company operates in three segments: patient services, product and research services. The patient services business segment’s principal focus is on the diagnosis and monitoring of cardiac arrhythmias or heart rhythm disorders, through its core Mobile Cardiac Outpatient Telemetry(MCOT), event and Holter services in a healthcare setting.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.